RxDoctor Payments DataLook up a doctor →

Nehal Modh, MD

Pain Medicine · Festus, MONPI 1619081890

Payments from drug & device makers

$16,690in general payments, 2019–2025

Across 1,044 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Abbott$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Collegium Pharmaceutical, Inc.$898
  • Pfizer$842
  • Amgen$763
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$16,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,690 in reported general payments places this provider in the 85th percentile of 124 pain medicine providers in Missouri.

See all pain medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$186,257
Medicare patients
125
Services billed
1,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate93$103,400
BelbucaBuprenorphine Hcl178$98,374
UbrelvyUbrogepant48$53,668
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,938$45,466
RelistorMethylnaltrexone Bromide14$32,714
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,566$30,210
Diclofenac Sodium128$25,465
QuliptaAtogepant23$25,421
HorizantGabapentin Enacarbil22$17,110
Pregabalin1,130$15,628
MovantikNaloxegol Oxalate35$13,918
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$9,874
Emgality PenGalcanezumab-Gnlm13$9,130
Xtampza ErOxycodone Myristate26$8,907
Aimovig AutoinjectorErenumab-Aooe12$8,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$898$107,282204 claims
PfizerNurtec Odt$842$103,40093 claims
AbbVieUbrelvy, Qulipta, Linzess$5,395$86,20183 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,861$32,71414 claims
Arbor Pharmaceuticals, Inc.Horizant$102$17,11022 claims
Redhill Biopharma Inc.Movantik$24$13,91835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 124 pain medicine providers in Missouri.

Other pain medicine in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →